M
Megumi Oshima
Researcher at Kanazawa University
Publications - 50
Citations - 909
Megumi Oshima is an academic researcher from Kanazawa University. The author has contributed to research in topics: Medicine & Kidney disease. The author has an hindex of 9, co-authored 33 publications receiving 253 citations. Previous affiliations of Megumi Oshima include Stanford University & The George Institute for Global Health.
Papers
More filters
Journal ArticleDOI
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
Meg Jardine,Zien Zhou,Kenneth W. Mahaffey,Megumi Oshima,Megumi Oshima,Rajiv Agarwal,George L. Bakris,Harpreet S. Bajaj,Scott Bull,Christopher P. Cannon,David M. Charytan,Dick de Zeeuw,Gian Luca Di Tanna,Tom Greene,Hiddo J.L. Heerspink,Adeera Levin,Bruce Neal,Bruce Neal,Bruce Neal,Carol A. Pollock,Rose Qiu,Tao Sun,David C. Wheeler,David C. Wheeler,Hong Zhang,Bernard Zinman,Norman Rosenthal,Vlado Perkovic,Vlado Perkovic +28 more
TL;DR: Canagliflozin safely reduced the risk of renal and cardiovascular events, with consistent results across eG FR subgroups, including the subgroup initiating treatment with an eGFR of 30 to <45 ml/min per 1.73 m2.
Journal ArticleDOI
Gut microbiota-derived D-serine protects against acute kidney injury
Yusuke Nakade,Yasunori Iwata,Kengo Furuichi,Masashi Mita,Kenji Hamase,Ryuichi Konno,Taito Miyake,Norihiko Sakai,Shinji Kitajima,Tadashi Toyama,Yasuyuki Shinozaki,Akihiro Sagara,Taro Miyagawa,Akinori Hara,Miho Shimizu,Yasutaka Kamikawa,Kouichi Sato,Megumi Oshima,Shiori Yoneda-Nakagawa,Yuta Yamamura,Shuichi Kaneko,Tetsuya Miyamoto,Masumi Katane,Hiroshi Homma,Hidetoshi Morita,Wataru Suda,Masahira Hattori,Takashi Wada +27 more
TL;DR: The renoprotective effects of gut-derived D-serine in AKI are demonstrated, light is shed on the interactions between the gut microbiota and the kidney in both health and AKI, and D-Serine is highlighted as a potential new therapeutic target and biomarker for AKI.
Journal ArticleDOI
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
Megumi Oshima,Megumi Oshima,Meg Jardine,Meg Jardine,Rajiv Agarwal,George Bakris,Christopher P. Cannon,David M. Charytan,Dick de Zeeuw,Robert Edwards,Tom Greene,Adeera Levin,Soo Kun Lim,Kenneth W. Mahaffey,Bruce Neal,Carol A. Pollock,Norman Rosenthal,David C. Wheeler,Hong Zhang,Bernard Zinman,Vlado Perkovic,Hiddo J.L. Heerspink,Hiddo J.L. Heerspink +22 more
TL;DR: Following the initial drop in eGFR, multivariable adjusted long-term eG FR trajectories, as well as overall and kidney safety profiles, in those treated with canagliflozin were similar across eGfr decline categories, and safety outcomes were similar among subgroups of acute e GFR drop.
Journal ArticleDOI
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.
George Bakris,Megumi Oshima,Megumi Oshima,Kenneth W. Mahaffey,Rajiv Agarwal,Christopher P. Cannon,George Capuano,David M. Charytan,Dick de Zeeuw,Robert Edwards,Tom Greene,Hiddo J.L. Heerspink,Hiddo J.L. Heerspink,Adeera Levin,Bruce Neal,Bruce Neal,Bruce Neal,Richard Oh,Carol A. Pollock,Norman Rosenthal,David C. Wheeler,David C. Wheeler,Hong Zhang,Bernard Zinman,Meg Jardine,Meg Jardine,Vlado Perkovic,Vlado Perkovic +27 more
TL;DR: A post hoc analysis suggests canagliflozin slowed progression of kidney disease, without increasing AKI, even in participants with eGFR <30 ml/min per 1.73 m2.
Journal ArticleDOI
Trajectories of kidney function in diabetes: a clinicopathological update
Megumi Oshima,Miho Shimizu,Masayuki Yamanouchi,Tadashi Toyama,Akinori Hara,Kengo Furuichi,Takashi Wada +6 more
TL;DR: In this paper, the authors discussed the trajectories of kidney function in patients with diabetes and their underlying factors, as well as their correlation with histopathological changes in the kidney and patient outcomes.